[go: up one dir, main page]

DK3653049T5 - Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse - Google Patents

Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse Download PDF

Info

Publication number
DK3653049T5
DK3653049T5 DK19204021.0T DK19204021T DK3653049T5 DK 3653049 T5 DK3653049 T5 DK 3653049T5 DK 19204021 T DK19204021 T DK 19204021T DK 3653049 T5 DK3653049 T5 DK 3653049T5
Authority
DK
Denmark
Prior art keywords
polynucleotides encoding
animals including
rodent antibodies
human idiotypes
encoding rodent
Prior art date
Application number
DK19204021.0T
Other languages
English (en)
Other versions
DK3653049T3 (da
Inventor
Marianne Bruggemann
Roland Buelow
Michael J Osborn
Biao Ma
Original Assignee
Omniab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50935093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3653049(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omniab Inc filed Critical Omniab Inc
Application granted granted Critical
Publication of DK3653049T3 publication Critical patent/DK3653049T3/da
Publication of DK3653049T5 publication Critical patent/DK3653049T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK19204021.0T 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse DK3653049T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737371P 2012-12-14 2012-12-14
EP13843056.6A EP2931030B2 (en) 2012-12-14 2013-12-13 Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same

Publications (2)

Publication Number Publication Date
DK3653049T3 DK3653049T3 (da) 2023-11-13
DK3653049T5 true DK3653049T5 (da) 2024-08-26

Family

ID=50935093

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19204021.0T DK3653049T5 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse
DK13843056.6T DK2931030T4 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13843056.6T DK2931030T4 (da) 2012-12-14 2013-12-13 Polynukleotider, der koder for graver-antistoffer med humane idiotyper, og dyr, der omfatter disse

Country Status (20)

Country Link
US (2) US9475859B2 (da)
EP (3) EP3653049B1 (da)
JP (1) JP6705650B2 (da)
KR (3) KR20220041953A (da)
CN (2) CN104994729B (da)
AU (2) AU2013358958B2 (da)
CA (1) CA2895144C (da)
CY (1) CY1123215T1 (da)
DK (2) DK3653049T5 (da)
ES (2) ES2963516T3 (da)
FI (2) FI3653049T3 (da)
HR (2) HRP20201160T4 (da)
HU (2) HUE050930T2 (da)
IL (2) IL239300B (da)
LT (2) LT3653049T (da)
PL (2) PL3653049T3 (da)
PT (2) PT2931030T (da)
SG (1) SG11201504676VA (da)
SI (2) SI3653049T1 (da)
WO (1) WO2014093908A2 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
GB2547587B (en) 2014-10-22 2020-12-09 Crescendo Biologics Ltd Transgenic mice
BR112017013104A2 (pt) * 2014-12-19 2018-05-15 Regeneron Pharma métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
CA2994825A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
PT3337824T (pt) 2015-08-17 2020-09-10 Janssen Pharmaceutica Nv Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações
MX2018003905A (es) 2015-09-30 2018-09-06 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
EP3371220A2 (en) 2015-11-02 2018-09-12 Janssen Pharmaceutica NV Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
EP3471773A4 (en) * 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
UA126384C2 (uk) 2016-09-14 2022-09-28 Тенеобіо, Інк. Антитіло, яке зв'язує cd3
IL266769B2 (en) * 2016-11-22 2024-04-01 Merck Patent Gmbh Monoclonal antibodies specific for fgfr1 and their preparation
WO2018095932A1 (en) * 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Anti-bcma heavy chain-only antibodies and uses thereof
SG10202109874VA (en) 2017-01-19 2021-10-28 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
MX2020006494A (es) * 2017-12-22 2020-11-24 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd22.
AU2019220395B2 (en) 2018-02-14 2025-12-04 Abba Therapeutics Ag Anti-human PD-L2 antibodies
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
CN110467674B (zh) 2018-05-11 2022-05-31 同润澳门一人有限公司 抗ox40的全人抗体及其制备方法和用途
AU2019270624B2 (en) 2018-05-16 2024-05-02 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
RS66901B1 (sr) 2018-05-24 2025-07-31 Janssen Biotech Inc Anti-cd3 antitela i njihova upotreba
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
AU2020226445B2 (en) * 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
CN113710707B (zh) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
CN119564852A (zh) 2019-06-14 2025-03-07 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
PH12022550196A1 (en) 2019-07-26 2022-11-21 Janssen Biotech Inc Anti-hk2 chimeric antigen receptor (car)
US12077585B2 (en) 2019-07-26 2024-09-03 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
JP2022550067A (ja) 2019-09-27 2022-11-30 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｅａｃａｍ抗体及びその使用
EP4038099A1 (en) 2019-10-03 2022-08-10 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
IL298046A (en) 2020-05-11 2023-01-01 Janssen Biotech Inc Methods for treating multiple myeloma
KR20230017841A (ko) 2020-05-27 2023-02-06 얀센 바이오테크 인코포레이티드 Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
TW202221028A (zh) 2020-07-29 2022-06-01 美商健生生物科技公司 包括hla-g抗原結合域之蛋白及其用途
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
KR20230142482A (ko) 2021-01-27 2023-10-11 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는면역접합체 및 이의 용도
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
JP2025504907A (ja) 2022-01-26 2025-02-19 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
TW202428603A (zh) 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白
CA3267628A1 (en) 2022-09-21 2024-03-28 Seagen Inc ANTIBODIES THAT BIND TO CD228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
US5411881A (en) 1990-07-10 1995-05-02 Nkk Corporation Chicken-specific immunoglobulin G-producing hybridoma
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
JPH08140528A (ja) * 1993-12-03 1996-06-04 Genpharm Internatl Inc 異種抗体を産生することができるトランスジェニック非ヒト動物
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
DE69738539T2 (de) * 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
ES2679282T3 (es) * 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
BRPI0706750A2 (pt) 2006-01-25 2011-04-05 Univ Erasmus Medical Ct geração de anticorpos de cadeia pesada em animais transgênicos
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2602323B1 (en) * 2007-06-01 2018-02-28 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination

Also Published As

Publication number Publication date
ES2813609T5 (es) 2024-08-09
PT2931030T (pt) 2020-08-03
DK2931030T3 (da) 2020-08-03
US20150113668A1 (en) 2015-04-23
JP6705650B2 (ja) 2020-06-03
DK2931030T4 (da) 2024-04-22
CN110042105B (zh) 2023-03-28
AU2018223041A1 (en) 2018-09-20
FI2931030T4 (fi) 2024-04-22
EP4269602A2 (en) 2023-11-01
HRP20231356T1 (hr) 2024-02-16
FI3653049T3 (fi) 2023-11-02
WO2014093908A2 (en) 2014-06-19
NZ749259A (en) 2020-09-25
HUE064063T2 (hu) 2024-02-28
PL2931030T5 (pl) 2024-06-10
SG11201504676VA (en) 2015-07-30
PL2931030T3 (pl) 2021-03-22
CA2895144C (en) 2024-04-16
AU2013358958B2 (en) 2018-09-20
SI3653049T1 (sl) 2024-02-29
AU2018223041B2 (en) 2020-06-25
NZ709608A (en) 2020-09-25
AU2013358958A1 (en) 2015-07-09
KR102239125B1 (ko) 2021-04-12
EP3653049B1 (en) 2023-09-13
HRP20201160T1 (hr) 2020-12-11
KR20150094720A (ko) 2015-08-19
ES2963516T3 (es) 2024-03-27
IL239300B (en) 2021-01-31
SI2931030T1 (sl) 2020-10-30
US9475859B2 (en) 2016-10-25
PT3653049T (pt) 2023-11-14
ES2813609T3 (es) 2021-03-24
KR20210040189A (ko) 2021-04-12
LT2931030T (lt) 2020-11-10
HRP20201160T4 (hr) 2024-10-11
CY1123215T1 (el) 2021-12-31
KR20220041953A (ko) 2022-04-01
CN110042105A (zh) 2019-07-23
SI2931030T2 (sl) 2024-06-28
CN104994729B (zh) 2019-01-11
US20170174770A1 (en) 2017-06-22
LT3653049T (lt) 2023-11-10
DK3653049T3 (da) 2023-11-13
EP3653049A1 (en) 2020-05-20
IL239300A0 (en) 2015-07-30
EP4269602A3 (en) 2023-12-27
EP2931030B2 (en) 2024-01-17
PL3653049T3 (pl) 2024-02-26
WO2014093908A3 (en) 2014-10-16
EP2931030A2 (en) 2015-10-21
EP2931030B1 (en) 2020-04-29
CN104994729A (zh) 2015-10-21
US10385132B2 (en) 2019-08-20
HUE050930T2 (hu) 2021-01-28
CA2895144A1 (en) 2014-06-19
JP2016505257A (ja) 2016-02-25
IL279716A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
DK3653049T5 (da) Polynukleotider, der koder for gnaverantistoffer med humane idiotyper, og dyr, der omfatter disse
DK3308641T3 (da) Immundeficient genmodificeret gnaver og fremgangsmåder til anvendelse deraf
DK2935326T3 (da) Humane anti-tau-antistoffer
DK2844672T3 (da) Humane antistoffer over for Fel d1 og fremgangsmåder til anvendelse deraf
BR112014029053A2 (pt) disposição de escovação e método de operação de disposição de escovação animal.
BR112013021785A8 (pt) animais geneticamente modificados e métodos para fazer os mesmos
DK2972351T3 (da) Forbedrede analysemetoder
HRP20160484T1 (hr) Životinje koje izražavaju antitijela sa zajedničkim lakim lancem
FI20155065A7 (fi) Monikäyttölaite eläimen hoitoon
LT3046412T (lt) Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112015003838A2 (pt) formulações de anticorpo e proteína
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
LT2819339T (lt) Komponentų laikmenos aktyvinimas ir pasyvinimas, naudojant išteklių paskirstymą
EP2863736A4 (en) GENETICALLY MODIFIED ANIMALS AND METHODS OF PRODUCTION THEREFOR
EP2966997A4 (en) ELECTRONIC PET CAP
DK3431492T3 (da) Humane cd30-ligandantigen-bindende proteiner
HUE053561T2 (hu) Állatõrzõ kerítés és eljárás annak összeszerelésére
DK2967018T3 (da) Apparat og fremgangsmåde til indfangning af akvatiske dyr
DK3016547T3 (da) Dyrebarriere og fremgangsmåde
DK2814843T3 (da) IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
BR112015008902A2 (pt) métodos de geração de animais geneticamente superiores.
BR112015010316A2 (pt) materiais biocompostos derivados de proteínas animais
DK2651979T3 (da) Humane anti-sod1-antistoffer
BR302012005516S1 (pt) Configuração aplicada em casinha de animais